Search results
8 lip 2022 · NEW YORK and MAINZ, GERMANY, July 8, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) approved the companies’ supplemental Biologics License Application (sBLA) for their COVID-19 vaccine, known as COMIRNATY® (COVID-19 Vaccine, mRNA), to include individuals 12 through ...
- Pfizer's year in review | Pfizer 2022 Annual Report
Pfizer can reach more patients with life-saving treatments,...
- Pfizer's year in review | Pfizer 2022 Annual Report
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination...
7 sty 2022 · Rather than producing 500 pages a month, the FDA’s proposed timeline, Pittman ordered the agency to turn over 55,000 a month. That means all the Pfizer vaccine data should be public by the end of...
In April 2022, the FDA authorized boosters for 5 through 11 years of age as well. During this time, a Phase 2/3 clinical trial was also underway to test a lower-strength version of our original COVID–19 vaccine as a three-dose primary series for children six months to under 5 years of age.
Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty...
15 paź 2024 · Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) Authorized For Individuals 6 Months through 11 Years of Age. On August 22, 2024, the Food and Drug Administration amended the emergency...
Pfizer can reach more patients with life-saving treatments, sooner. Since 2019, we’ve decreased our median first-in-human to approval development timeline for new medicines and vaccines from nine years to approximately five years in 2022.
